ICAD Stock Overview
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
iCAD, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.55 |
| 52 Week High | US$3.97 |
| 52 Week Low | US$1.05 |
| Beta | 1.42 |
| 1 Month Change | 15.67% |
| 3 Month Change | -32.02% |
| 1 Year Change | -13.89% |
| 3 Year Change | -84.17% |
| 5 Year Change | -62.01% |
| Change since IPO | -96.94% |
Recent News & Updates
Recent updates
We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely
Sep 27
We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully
Jun 21Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?
Feb 10Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?
Nov 09Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth
Jun 24iCAD (NASDAQ:ICAD) Is In A Good Position To Deliver On Growth Plans
Feb 23iCAD: Downside Seems Limited
Jan 16iCAD, Inc. (NASDAQ:ICAD) Analysts Just Cut Their EPS Forecasts Substantially
Jan 06Here's Why We're Not Too Worried About iCAD's (NASDAQ:ICAD) Cash Burn Situation
Nov 11Is It Too Late To Consider Buying iCAD, Inc. (NASDAQ:ICAD)?
Jun 25iCAD inks global distribution agreement with Sectra
Jun 08Is iCAD (NASDAQ:ICAD) Weighed On By Its Debt Load?
May 31Is iCAD, Inc. (NASDAQ:ICAD) Trading At A 39% Discount?
May 16iCAD, Inc. (NASDAQ:ICAD): Is Breakeven Near?
Mar 19Is iCAD, Inc.'s (NASDAQ:ICAD) Shareholder Ownership Skewed Towards Insiders?
Mar 02Shareholder Returns
| ICAD | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 19.2% | -0.7% | 0.09% |
| 1Y | -13.9% | -9.7% | 10.4% |
Return vs Industry: ICAD underperformed the US Healthcare Services industry which returned -5.5% over the past year.
Return vs Market: ICAD underperformed the US Market which returned 13.3% over the past year.
Price Volatility
| ICAD volatility | |
|---|---|
| ICAD Average Weekly Movement | 10.0% |
| Healthcare Services Industry Average Movement | 8.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ICAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ICAD's weekly volatility has decreased from 16% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 109 | Dana Brown | https://www.icadmed.com |
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company’s breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography.
iCAD, Inc. Fundamentals Summary
| ICAD fundamental statistics | |
|---|---|
| Market Cap | US$41.37m |
| Earnings (TTM) | -US$12.54m |
| Revenue (TTM) | US$25.36m |
1.6x
P/S Ratio-3.3x
P/E RatioIs ICAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICAD income statement (TTM) | |
|---|---|
| Revenue | US$25.36m |
| Cost of Revenue | US$7.72m |
| Gross Profit | US$17.64m |
| Other Expenses | US$30.18m |
| Earnings | -US$12.54m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.48 |
| Gross Margin | 69.57% |
| Net Profit Margin | -49.45% |
| Debt/Equity Ratio | 0% |
How did ICAD perform over the long term?
See historical performance and comparison